Search Results

You are looking at 81 - 90 of 482 items for :

  • "adjuvant chemotherapy" x
  • Refine by Access: All x
Clear All
Full access

Pranab Kumar Sahoo, Sinjini Sarkar, Sutapa Mahata, Ranita Pal, Tanuma Mistry, Sushmita Ghosh, Trisha Choudhury, Sriparna Datta, Anup Kumar Bhowmick, Kalyan Kusum Mukherjee, and Vilas D Nasare

maximum number of patients diagnosed with SCC (36%) received adjuvant chemotherapy (56.7%). 25.6% patients underwent TPF chemotherapy while 74.4% of patients went for PC chemotherapeutic regimen. Patients mainly experienced grade III and IV haematological

Full access

Kushal Naha, Abdulmateen Adebiyi, Praveen Rao, and Christos Papageorgiou

positive node negative breast cancers <1 cm often do not need adjuvant chemotherapy while those with stage III disease typically do. Unfortunately, most cases of breast cancer fall between these two extremes and require additional genomics and

Full access

Kevin Zhang, Ladan Navari, Amy Li, Sandy Lee, Yevgeniya Gokun, Min-Jeong Cho, Roman Skoracki, and Ko Un Park

.2% PLVB vs 31.9% without PLVB) but completed fewer post-op PT appointments (p<0.0001) (Table1). Patients who received neoadjuvant chemotherapy or adjuvant radiation were more likely to have a pre-op PT appointment, while those who received either adjuvant

Full access

Lindsay A. Gil, Mariam F. Eskander, Samilia Obeng-Gyasi, Bridget A. Oppong, Yaming Li, and Allan Tsung

receiving fragmented care (treatment at multiple facilities) and its implications on receipt of GCC. Methods: The National Cancer Database (NCDB) 2006-2016 was queried for patients with pancreatic adenocarcinoma who underwent resection and adjuvant

Full access

Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Full access

/18/14 NCCN Guidelines® Insights: Metastatic Colon Cancer, Version 3.2013 Expiration Date: 2/18/14 Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer Expiration Date: 2/18/14 CASE REPORT: Adjuvant Chemotherapy Decisions in Clinical

Full access

Jagar Jasem, Christine M. Fisher, Arya Amini, Elena Shagisultanova, Rachel Rabinovitch, Virginia F. Borges, Anthony Elias, and Peter Kabos

Background Adjuvant chemotherapy was once considered the standard of care for patients with primary breast cancer with tumors >1 cm regardless of axillary lymph node involvement. 1 – 3 However, given disease recurrence rates of <20% by 10

Full access

Lucy X. Ma, Elan D. Panov, Michael J. Allen, Gail E. Darling, Jonathan C. Yeung, Carol J. Swallow, Savtaj S. Brar, Rebecca K. Wong, Patrick Veit-Haibach, Sangeetha N. Kalimuthu, Eric X. Chen, Raymond W. Jang, and Elena Elimova

standardized approach and notable geographic variation in treatment exists. Up-front surgery with adjuvant chemotherapy is favored in Asian countries, whereas neoadjuvant or perioperative treatment is preferred in Europe and North America. 8 – 11 The

Full access

Betsy L. Althaus

Jones RJ Davidson NE . Myeloid toxicity in breast cancer patients receiving adjuvant chemotherapy with pegfilgrastim support (letter) . J Clin Oncol 2006 ; 24 : 2392 – 2394 . 16. Brusamolino E Rusconi C Montalbetti L . Dose-dense R

Full access

Tara M. Breslin, Marcy Waldinger, and Samuel M. Silver

UMCCC experienced more rapid transition from biopsy to surgery or neoadjuvant chemotherapy, and surgery to adjuvant chemotherapy than those who received a portion of their care outside the center. This finding is not surprising, because EHR and internal